161 related articles for article (PubMed ID: 18234403)
1. Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.
D'Andrea G; D'Ambrosio R; Margaglione M
Blood Rev; 2008 May; 22(3):127-40. PubMed ID: 18234403
[TBL] [Abstract][Full Text] [Related]
2. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of coumarinic oral anticoagulants.
Manolopoulos VG; Ragia G; Tavridou A
Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].
Loriot MA; Beaune P
Rev Prat; 2007 Jun; 57(12):1281-6. PubMed ID: 17717937
[TBL] [Abstract][Full Text] [Related]
5. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
[TBL] [Abstract][Full Text] [Related]
6. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T; Miyata T
Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.
Scibona P; Redal MA; Garfi LG; Arbelbide J; Argibay PF; Belloso WH
Genet Mol Res; 2012 Jan; 11(1):70-6. PubMed ID: 22290467
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of vitamin K antagonists: useful or hype?
Lippi G; Franchini M; Favaloro EJ
Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
[TBL] [Abstract][Full Text] [Related]
9. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants].
Becquemont L; Verstuyft C; Jaillon P
Bull Acad Natl Med; 2006 Jan; 190(1):37-49; discussion 50-3. PubMed ID: 16878445
[TBL] [Abstract][Full Text] [Related]
11. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
Siguret V; Pautas E; Gouin-Thibault I
Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
[TBL] [Abstract][Full Text] [Related]
12. [Application of warfarin pharmacogenetics].
Tomek A; Mat'oska V; Kumstýrfová T; Táborský L
Vnitr Lek; 2009 Jun; 55(6):565-9. PubMed ID: 19662888
[TBL] [Abstract][Full Text] [Related]
13. [Factors influencing the variable response to treatment with oral anticoagulants].
Kucharska K; Popczak G; Prystupa A; Mosiewicz J
Wiad Lek; 2012; 65(1):38-43. PubMed ID: 22827114
[TBL] [Abstract][Full Text] [Related]
14. The pharmocogenomics of warfarin: closing in on personalized medicine.
Rettie AE; Tai G
Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
[TBL] [Abstract][Full Text] [Related]
15. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.
Schwarz UI; Stein CM
Clin Pharmacol Ther; 2006 Jul; 80(1):7-12. PubMed ID: 16815312
[No Abstract] [Full Text] [Related]
16. Pharmacogenetics of target genes across the warfarin pharmacological pathway.
Lal S; Jada SR; Xiang X; Lim WT; Lee EJ; Chowbay B
Clin Pharmacokinet; 2006; 45(12):1189-200. PubMed ID: 17112295
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic-based dosing of warfarin.
Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
[No Abstract] [Full Text] [Related]
18. [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].
Siguret V
Pathol Biol (Paris); 2007 Jul; 55(6):295-8. PubMed ID: 17611042
[TBL] [Abstract][Full Text] [Related]
19. [The pharmacogenetics of vitamin K antagonists: still a matter for discussion].
Moreau C; Siguret V; Loriot MA
Rev Med Interne; 2010 May; 31(5):361-8. PubMed ID: 20362363
[TBL] [Abstract][Full Text] [Related]
20. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
